Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.
about
Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4Dealing with the complex drug-drug interactions: towards mechanistic models.Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes.Letter: depression and the use of anti-depressants in patients with chronic liver disease or liver transplantation - authors' reply.
P2860
Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Stereoselective inhibition of ...... e-dependent inhibitor systems.
@en
Stereoselective inhibition of ...... e-dependent inhibitor systems.
@nl
type
label
Stereoselective inhibition of ...... e-dependent inhibitor systems.
@en
Stereoselective inhibition of ...... e-dependent inhibitor systems.
@nl
prefLabel
Stereoselective inhibition of ...... e-dependent inhibitor systems.
@en
Stereoselective inhibition of ...... e-dependent inhibitor systems.
@nl
P2093
P2860
P356
P1476
Stereoselective inhibition of ...... e-dependent inhibitor systems.
@en
P2093
Brooke M VandenBrink
Justin D Lutz
Katipudi N Babu
Kent L Kunze
Nina Isoherranen
Wendel L Nelson
P2860
P304
P356
10.1124/DMD.113.052639
P577
2013-06-19T00:00:00Z